Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(33%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
1
17%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

withdrawn117%
completed350%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
completedphase_3

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

NCT06135415
recruitingphase_2

Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

NCT06112522
recruiting

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

NCT07657988
completed

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073
withdrawnphase_4

Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands

NCT06026358
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06135415Phase 3

A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

Completed
NCT06112522Phase 2

Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

Recruiting
NCT07657988

Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)

Recruiting
NCT05260073

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

Completed
NCT06026358Phase 4

Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands

Withdrawn
NCT05900258Phase 4

Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6